The US biotech company Maxygen, is now revitalising its activities in Denmark with new staff and clinical testing of an anti-infection substance in humans. Maxygen is creating 11 new jobs at its Hørsholm facility north of Copenhagen, which will bring the total headcount to 95 during this year. The planned programme of human tests in Denmark comes nine years after the company was founded.
Torben Nissen, who is returning from a period with Maxygen in the US to lead the Danish operation, comments: "Maxygen was a technology company, and it has taken a good deal of internal discussion and longer than expected to set the focus on product development." Nissen also adds that progress was slowed by poor capital market conditions at the start of the decade.
The first project, planned to go into human clinical testing this year, is a substance designed to stimulate white blood cells so that cancer patients undergoing chemotherapy are better protected against the risk of serious infections. A follow-on project in collaboration with Switzerland's Roche, that may also be put into clinical development this year, is a treatment for liver disease.
In its entirety, Maxygen employs 150 people, with clinical development competencies concentrated in Denmark. The company is headquartered in Redwood City, California. Maxygen which is listed on Nasdaq, has more than DKK 1 bn (USD 160 m) cash in hand. The news was reported by financial daily newspaper Børsen.
Link > Maxygen